Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 172

The DOI matches its Crossref record.

Extracellular Tyrosinase mRNA within Apoptotic Bodies Is Protected from Degradation in Human Serum

Hasselmann, Dirk O, Rappl, Gunter, Tilgen, Wolfgang, Reinhold, Uwe · 2001 · Clinical Chemistry

Abstract

The amplification of tyrosinase mRNA by reverse transcription-PCR (RT-PCR) from peripheral blood has frequently been used as a marker for the presence of circulating tumor cells in melanoma patients (1). Recently, tyrosinase mRNA was also demonstrated to be detectable in serum and plasma samples from melanoma patients, indicating that tumor-specific mRNA is present in an extracellular form in the bloodstream (2)(3). This has been confirmed by other investigators demonstrating the presence of extracellular telomerase mRNA in the serum of breast cancer patients (4). It has been speculated that the presence of tumor-associated mRNA in serum and plasma is possibly related to tumor cell necrosis and release of transcripts into the circulation. Furthermore, there is evidence to suggest that mRNA may be actively secreted by tumor cells in vivo (5)(6). It is not yet clear, however, how serum and plasma mRNA is protected from RNases. Several findings have indicated that extracellular RNA might be protected from serum RNases by proteins or proteolipid complexes (6)(7)(8). Very recently, it was demonstrated that DNA and RNA are packaged separately into apoptotic bodies, producing two types of apoptotic bodies, one type containing RNA and no DNA and the other type containing DNA and no RNA (9). This finding suggests that extracellular mRNA may circulate within apoptotic bodies, which may decrease their susceptibility to nucleases. The present study was therefore conducted to analyze the serum stability of tyrosinase mRNA associated with apoptotic bodies in comparison with free tyrosinase transcripts. Cells (1 × 106 cells/well) of the melanoma cell line Bu-Hom (established in our laboratory from a patient’s lymph node metastasis) were plated in 6-well tissue culture plates (Costar) in 2 mL of medium consisting of Dulbecco’s modified Eagle’s medium containing 100 mL/L fetal serum and incubated at 37 °C in 10% CO2. Cells were allowed to adhere overnight. Apoptosis of melanoma cells was induced by the addition of the agonistic cross-linking anti-CD95 monoclonal antibody 7C11 (50 μg/L; Immunotech) for 48 h. At the termination of culture, cell-free supernatants were collected and passed through a 0.45 μm filter. Induction of apoptotic cell death and apoptotic bodies was confirmed by different methods. In the first method, melanoma cells were precisely analyzed by light microscopy, and morphologic changes characterizing apoptotic cell death were identified. In the second method, apoptotic bodies present in collected cell-free supernatants were identified by double staining and subsequent flow cytometry using fluorescein isothiocyanate-labeled annexin V, a marker for early and late apoptosis, and propidium iodide, a marker for late apoptosis and necrosis (TACS Annexin V Apoptosis Detection reagent set; Genzyme). These studies confirmed the presence of apoptotic bodies in culture supernatants of melanoma cells incubated with monoclonal antibody 7C11. In the third method, apoptotic bodies present in supernatants were attached to microscope slides, fixed in ice-cold solution containing 10 g/L methanol-free formaldehyde in phosphate-buffered saline for 15 min, and postfixed in cold 700 mL/L ethanol for at least 2 h. The presence of RNA in apoptotic bodies was confirmed by staining with pyronin Y (20 mg/L; Sigma). Fluorescence microscopy (570 nm) identified typical granular structures representing apoptotic bodies that contained RNA. Cell-free supernatant (1 mL) from 1 × 106 cultured melanoma cells was mixed with 2 mL of fresh serum from controls and incubated at 37 °C for different periods of time. As a control, 1 μg of free total RNA isolated from Bu-Hom melanoma cells was mixed with normal serum. After the indicated time points, serum samples were stabilized with RNA/DNA Stabilization Reagent for Blood/Bone Marrow (Roche Diagnostics). Poly(A)+ mRNA was extracted using the mRNA Isolation Kit for Blood and Bone Marrow (Roche Diagnostics) according to the manufacturer’s protocol. cDNA was synthesized and amplified in a 50-μL PCR reaction using the Qiagen One Step RT-PCR reagent set (Qiagen). In brief, 6 μL of mRNA was reverse-transcribed with specific primers for tyrosinase, using One Step RT-PCR enzyme mixture (Qiagen), and then amplified in the following PCR reaction using HotStarTaq DNA polymerase (Qiagen). The following tyrosinase primers were used in PCR reactions: 5′-TTGGCAGATTGTCTGTAGCC-3′ (sense) and 5′-AGGCATTGTGCATGCTGCTT-3′ (antisense). Cycling conditions were as follows: for reverse transcription of mRNA, 30 min at 50 °C; for amplification of cDNA, an initial denaturation step of 15 min at 95 °C, followed by 20 s of denaturation at 94 °C, 20 s of annealing at 58 °C, and 40 s of extension at 72 °C. The PCR was cycled 60 times. PCR products were electrophoresed in a 1% agarose gel containing ethidium bromide and visualized under ultraviolet light. We detected no tyrosinase-specific mRNA in serum samples mixed with free tu

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/clinchem/47.8.1488

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 172

Metadata

Authors
Hasselmann, D. O., Rappl, G., Tilgen, W., & Reinhold, U.
Venue
Clinical Chemistry
Published
2001-08-01
Volume
47
Issue
8
Pages
1488-1489
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2130187402
Cited by
172
References
0
FWCI
2.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extracellular Tyrosinase mRNA within Apoptotic Bodies Is Protected from Degradation in Human Serum. https://app.cochat.ai/papers/10.1093/clinchem/47.8.1488
The paper
Hasselmann, D. O., Rappl, G., Tilgen, W., & Reinhold, U. (2001). Extracellular Tyrosinase mRNA within Apoptotic Bodies Is Protected from Degradation in Human Serum. Clinical Chemistry. https://doi.org/10.1093/clinchem/47.8.1488

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.